Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [14C] Yiqibuvir
Yiqibuvir · 1 trial · 1 indication
Percent (%) of each radiolabeled drug-related material (parent and each metabolite) will be determined in plasma, urine and feces.
| Arm | Type | Description |
|---|---|---|
| [14C] Yiqibuvir | EXPERIMENTAL | Eligible healthy male subjects received a single oral 600 mg (radioactivity of 100µCi) dose of \[14C\] Yiqibuvir |
| Name | Type | Description |
|---|---|---|
| [14C] Yiqibuvir | DRUG | 600 mg suspension containing 100µCi of \[14C\] Yiqibuvir |
Inclusion Criteria: * signing of informed consent * Weight: Body mass index (BMI) is 19.0\~28.0 kg/m2 * Subjects are able to communicate well with the investigators and be able to complete the trial according to the process Exclusion Criteria: * Those who are known to have allergy history or alle...
Yiqibuvir is an investigational small molecule drug developed by Sunshine Biopharma Inc. (ticker SBFM). It has been studied in a Phase 1 clinical trial in healthy male subjects. The specific disease or condition it is intended to treat has not been disclosed.
Yiqibuvir is being developed by Sunshine Biopharma Inc., which trades under the ticker symbol SBFM. The company sponsored a Phase 1 ADME study of the drug in healthy male subjects in China.
Yiqibuvir is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA.
Yiqibuvir has been evaluated in one completed Phase 1 trial, NCT05998304, titled ADME Study of [14C] Yiqibuvir in Healthy Male Subjects. The trial enrolled 8 healthy male volunteers in China, was uncontrolled, and was not randomized or double blinded.
Yes, [14C] Yiqibuvir is an alternative name for Yiqibuvir. The carbon-14 labeled form was used in the Phase 1 ADME study, NCT05998304, to track how the drug is absorbed, distributed, metabolized, and excreted in the body.